Arlene Siefker-Radtke

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, and Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Urol 172:481-4. 2004
  2. ncbi request reprint Systemic chemotherapy options for metastatic bladder cancer
    Arlene Siefker-Radtke
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1374, Houston, TX 77030 3721, USA
    Expert Rev Anticancer Ther 6:877-85. 2006
  3. doi request reprint Urachal adenocarcinoma: a clinician's guide for treatment
    Arlene Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 39:619-24. 2012
  4. pmc A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:540-7. 2013
  5. ncbi request reprint Urachal carcinoma: surgical and chemotherapeutic options
    Arlene Siefker-Radtke
    The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1155 Herman Pressler Unit 1374, Houston, TX 77030 3721, USA
    Expert Rev Anticancer Ther 6:1715-21. 2006
  6. doi request reprint Bladder cancer: can we move beyond chemotherapy?
    Arlene Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA
    Curr Oncol Rep 12:278-83. 2010
  7. doi request reprint Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, Urology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:2592-7. 2009
  8. doi request reprint A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
  9. pmc Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center
    Siobhan P Lynch
    Department of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 64:307-13. 2013
  10. doi request reprint p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells
    Lauren Marquis
    Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 13:477-86. 2012

Collaborators

Detail Information

Publications28

  1. ncbi request reprint Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, and Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Urol 172:481-4. 2004
    ..Neuroendocrine tumors of the bladder comprise a small subset of all bladder tumors. To improve our understanding of this tumor and define outcomes with current management, we performed a retrospective review of these cases...
  2. ncbi request reprint Systemic chemotherapy options for metastatic bladder cancer
    Arlene Siefker-Radtke
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1155 Herman Pressler, Unit 1374, Houston, TX 77030 3721, USA
    Expert Rev Anticancer Ther 6:877-85. 2006
    ....
  3. doi request reprint Urachal adenocarcinoma: a clinician's guide for treatment
    Arlene Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 39:619-24. 2012
    ..A recent clinical trial of 5-fluorouracil, leucovorin, gemcitabine, and cisplatin has recently completed accrual in metastatic urachal carcinoma, with patients now in long-term follow-up...
  4. pmc A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 119:540-7. 2013
    ..Sequential chemotherapy also has not been well studied in the neoadjuvant setting. The authors explored sequential neoadjuvant ifosfamide-based chemotherapy in a patient cohort at high risk of noncurative cystectomy...
  5. ncbi request reprint Urachal carcinoma: surgical and chemotherapeutic options
    Arlene Siefker-Radtke
    The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1155 Herman Pressler Unit 1374, Houston, TX 77030 3721, USA
    Expert Rev Anticancer Ther 6:1715-21. 2006
    ..There is no standard chemotherapy regimen for these patients; however, there is new-found hope with a currently accruing clinical trial exploring a 5-fluorouracil-based chemotherapy combination in this patient population...
  6. doi request reprint Bladder cancer: can we move beyond chemotherapy?
    Arlene Siefker-Radtke
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1155 Pressler Street, Houston, TX 77030, USA
    Curr Oncol Rep 12:278-83. 2010
    ..It is hoped that through these efforts we may soon move beyond the traditional cytotoxic chemotherapy paradigm, developing combinations that are more active and less toxic for all patients with urothelial cancer...
  7. doi request reprint Phase II clinical trial of neoadjuvant alternating doublet chemotherapy with ifosfamide/doxorubicin and etoposide/cisplatin in small-cell urothelial cancer
    Arlene O Siefker-Radtke
    Department of Genitourinary Medical Oncology, Urology, and Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:2592-7. 2009
    ..We now report results from the first phase II clinical trial developed exclusively for SCUC, to our knowledge...
  8. doi request reprint A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
    ..We assessed the clinical activity and safety of gemcitabine plus capecitabine in patients with metastatic renal cell cancer previously treated with immunotherapy...
  9. pmc Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center
    Siobhan P Lynch
    Department of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 64:307-13. 2013
    ..Small cell urothelial carcinoma (SCUC) is a rare, aggressive malignancy with a propensity for early microscopic metastases. Data suggest that neoadjuvant chemotherapy may lead to improved survival compared with initial surgery...
  10. doi request reprint p63 expression correlates with sensitivity to the Eg5 inhibitor ZD4877 in bladder cancer cells
    Lauren Marquis
    Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer Biol Ther 13:477-86. 2012
    ..Our data also suggest that anti-mitotics and cisplatin target different subsets of bladder cancer cells, a conclusion that may have important implications for the therapy of muscle-invasive bladder cancers...
  11. pmc P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors
    Wassim Kassouf
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Eur Urol 52:769-74. 2007
    ..To improve our understanding of its significance in a contemporary series, we performed an outcomes analysis of this cohort of patients...
  12. doi request reprint Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
    David J McConkey
    Department of Urology, U T M D Anderson Cancer Center, P O Box 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer Metastasis Rev 28:335-44. 2009
    ..The results suggest that EMT coordinately regulates drug resistance and muscle invasion/metastasis in urothelial cancer and is a dominant feature of overall cancer biology...
  13. pmc The p63 protein isoform ΔNp63α inhibits epithelial-mesenchymal transition in human bladder cancer cells: role of MIR-205
    Mai N Tran
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77054, USA
    J Biol Chem 288:3275-88. 2013
    ..Together, our data demonstrate that ΔNp63α-mediated expression of miR-205 contributes to the regulation of EMT in bladder cancer cells and identify miR-205 as a molecular marker of the lethal subset of human bladder cancers...
  14. ncbi request reprint Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
    ..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
  15. pmc p63 expression defines a lethal subset of muscle-invasive bladder cancers
    Woonyoung Choi
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e30206. 2012
    ..Previous studies demonstrated that p63 is downregulated in muscle-invasive bladder cancers, but the relationship between p63 expression and survival is not clear...
  16. pmc Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression
    David J McConkey
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Urol Oncol 28:429-40. 2010
    ..This review will provide an overview of these new insights and discuss priorities for future investigation...
  17. ncbi request reprint Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology and Department of Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030 4009, USA
    J Urol 171:145-8. 2004
    ..The role of surgery for metastatic disease is not well established for urothelial cancer, but is sometimes undertaken in the face of persistent or recurrent disease that can be surgically resected...
  18. ncbi request reprint Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients
    Ashish M Kamat
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:62-7. 2007
    ..Micropapillary bladder carcinoma is a rare variant of urothelial carcinoma. To improve understanding of this disease, the authors performed a retrospective review of their experience...
  19. doi request reprint Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma
    Surena F Matin
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3127-34. 2010
    ....
  20. ncbi request reprint Neoadjuvant chemotherapy for bladder cancer
    Randall Millikan
    Department of Genitourinary Medical Oncology, Genitourinary Center, University of Texas, M D Anderson Cancer Center, Houston, TX 77033, USA
    Urol Oncol 21:464-7. 2003
    ..The authors make an appeal for a biologically (in contrast to anatomically) based staging system, and urge that perioperative chemotherapy be given with standard combinations with curative intent...
  21. ncbi request reprint Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience
    Wassim Kassouf
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 175:2058-62. 2006
    ..Partial cystectomy is a surgical option for select patients diagnosed with urothelial carcinoma. We review our experience with partial cystectomy for muscle invasive urothelial carcinoma to assess local control and survival rates...
  22. doi request reprint Identification of distinct Basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy
    Woonyoung Choi
    Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Cell 25:152-65. 2014
    ..Our observations have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy. ..
  23. doi request reprint miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy
    Liana Adam
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:5060-72. 2009
    ..The aims of this study were to determine the potential role of microRNAs (miRNA) in controlling EMT and the role of EMT in inducing the sensitivity of human bladder cancer cells to the inhibitory effects of the anti-EGFR therapy...
  24. ncbi request reprint Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ..The purpose of the study was to evaluate the efficacy and safety of a bone-targeted regimen consisting of zoledronate, thalidomide, and interferon-gamma in patients with renal cell carcinoma and bone metastases...
  25. doi request reprint Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells
    Peter C Black
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1478-86. 2008
    ..The aim of this study was to define molecular markers of response to cetuximab therapy in a panel of urothelial carcinoma cell lines...
  26. ncbi request reprint Focus on bladder cancer
    Colin P N Dinney
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, TX USA
    Cancer Cell 6:111-6. 2004
  27. ncbi request reprint Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    J Urol 169:1295-8. 2003
    ..To improve our understanding of urachal carcinoma and define outcome with current management, we performed a retrospective review of cases seen at the M. D. Anderson Cancer Center...
  28. ncbi request reprint Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer
    Arlene O Siefker-Radtke
    Center for Genitourinary Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1361-7. 2002
    ..The purpose of this study was to compare the response rates and overall survival of patients with metastatic or unresectable urothelial cancer treated with these two chemotherapy regimens...